Evaluating the efficacy of tissue-engineered human amniotic membrane in the treatment of myocardial infarction.
CONCLUSION: Histological and immunohistochemical evaluations indicated the regeneration of cardiomyocytes and reduction of inflammation and fibrosis in the patch-implanted group compared with a control group, 14 days after the surgery. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate biotin nick-end labeling assay was suggestive for apoptosis reduction in the patch-implanted specimens. This study suggested that human AM can be developed into a novel treatment for treating postmyocardial infarction.
PMID: 30741604 [PubMed - as supplied by publisher]
Source: Regenerative Medicine - Category: Genetics & Stem Cells Authors: Khorramirouz R, Kameli SM, Fendereski K, Daryabari SS, Kajbafzadeh AM Tags: Regen Med Source Type: research
More News: Cardiology | Genetics | Heart | Heart Attack | Stem Cell Therapy | Stem Cells | Study | Vitamin B7